HTFL trades 35.6% below Wall Street's consensus target of $37.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HTFL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Heartflow, Inc. Common Stock (HTFL) has a Wall Street consensus price target of $37.00, based on estimates from 4 covering analysts. With the stock currently trading at $27.29, this represents a potential upside of +35.6%. The company has a market capitalization of $10.06B.
Analyst price targets range from a low of $37.00 to a high of $37.00, representing a 0% spread in expectations. The median target of $37.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HTFL trades at a trailing P/E of -85.3x. Analysts expect EPS to grow -62.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
IRTCiRhythm Technologies, Inc. | $4.1B | $125.09 | $188.75 | +50.9% | Buy | — | 20 |
RXRXRecursion Pharmaceuticals, Inc. | $1.7B | $3.84 | $5.50 | +43.2% | Hold | — | 10 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
GEHCGE HealthCare Technologies Inc. | $29.5B | $64.89 | $81.00 | +24.8% | Buy | 13.3x | 18 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
NVDANVIDIA Corporation | $4.8T | $196.93 | $316.79 | +60.9% | Buy | 21.9x | 79 |
Quick answers to the most common questions about buying HTFL stock.
The consensus Wall Street price target for HTFL is $37, representing 35.6% upside from the current price of $27.29. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
HTFL has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $37 implies 35.6% upside from current levels.
HTFL's current price is $27.29 with a consensus target of $37 (35.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $37 for HTFL, while the most conservative target is $37. The consensus of $37 represents the median expectation. These targets typically reflect 12-month expectations.
HTFL is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HTFL stock forecast based on 4 Wall Street analysts shows a consensus price target of $37, with estimates ranging from $37 (bear case) to $37 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on HTFL, with a "Buy" consensus rating and $37 price target (35.6% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HTFL analyst price targets range from $37 to $37, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $37 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.